期刊文献+

PD-1在外周T/NK细胞淋巴瘤患者中的表达及其对患者预后的影响 被引量:6

PD-1 expression on the surface of peripheral blood CD4^+ T cell and its association with the prognosis of patients with peripheral T/NK cell lymphoma
原文传递
导出
摘要 外周T/NK细胞淋巴瘤(peripheral T/natural killer-cell lymphomas, PT/NKCL)是一种具有显著异质性的侵袭性非霍奇金淋巴瘤,其化疗敏感性差,预后不良,探讨其发病机制并寻找相应的药物靶点对提高患者的缓解率和生存率非常重要。PD-1(programmed death-1)是免疫球蛋白超家族的Ⅰ型跨膜糖蛋白,参与机体T细胞的免疫调节。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第10期916-918,共3页 Chinese Journal of Hematology
  • 相关文献

参考文献10

  • 1Wherry EJ. T cell exhaustion [Jl, Nat Immunol, 2011, 12(6): 492-499.
  • 2Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis [J], Circ Res, 2008, 103 (11): 1220-1231. doi: 10.1161/CIRCRESAHA.108.182428.
  • 3Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms [J].Mol Cell Biol, 2005, 25 (21): 9543-9553. doi: 10.1128/ MCB.25.21.9543-9553.2005.
  • 4Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies[J]. Clin Cancer Res, 2013, 19 ( 13 ): 3462 -3473. doi: 10.1158/1078 -0432 .CCR- 13 -0855.
  • 5李义,王晶,克晓燕.PD-L1在淋巴瘤中的表达及其对淋巴瘤增殖和化疗抵抗的初步研究[J].中国实验血液学杂志,2013,21(2):366-370. 被引量:12
  • 6Kozako T, Yoshimitsu M, Fujiwara H, et al. PD-1/PD-L 1 expres- sion in human T-cell leukemia virus type 1 carriers and adult T- cell leukemia/lymphoma patients [ J ]. Leukemia, 2009, 23 (2): 375-382. doi: 10.1038/leu.2008.272.
  • 7Krishnan C, Warnke RA, Arber DA, et al. PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lyrnphadenitis [J]. Am J Surg Pathol, 2010, 34 (2): 178-189. doi: 10.1097/PAS.0b013e318 lcc7e79.
  • 8Hawkes EA, Grigg A, Chong G. Programmed cell death-1 inhibi- tion in lymphoma [Jl. Lancet Oncol, 2015, 16 (5): e234-245. doi: 10.1016/S1470-2045( 15)70103-8.
  • 9MacFarlane AW, Jillab M, Plimack ER, et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection [J]. Cancer Immunol Res, 2014, 2 (4): 320-331. doi: 10.1158/2326-6066.CIR-13-0133.
  • 10Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study [J]. J Clin Oncol, 2016, doi: 10.1200/JCO.2015.65.9789.

二级参考文献15

  • 1Dong HD,Zhu GF,Tamada K,et al. B7-H1,a third member ofthe B7 family,co-stimulates T-cell proliferation and interieukin-lOsecretion. Nat Med,1999; 5(12) :1365 -1369.
  • 2Dong H,Strome SE,Salomao DR,et al. Tumor-associated B7-H1promotes T-cell apoptosis :A potential mechanism of immuneevasion. Nat Med,2002; 8(8) :793 -800.
  • 3Gottesman MM. Mechanisms of cancer drug resistance. Ann RevMed,2002 ; 53:615 -627.
  • 4Ramp U,Dejosez M,Mahotka C,et al. Deficient activation ofCD95 ( APO-1/Fas ) -mediated apoptosis :a potential factor ofmultidrug resistance in human renal cell carcinoma. Br J Cancer,2000 ; 82(11) :1851 -1859.
  • 5Friesen C,Fulda S,Debatin KM. Deficient activation of the CD95(APO-1/Fas) system in drug-resistant cells. Leukemia,1997; 11(U):1833 -1841.
  • 6Vucic D,Stennicke HR,Pisabarro MT,et al. ML-IAP,a novelinhibitor of apoptosis that is preferentially expressed in humanmelanomas. Curr Biol,2000; 10(21) ; 1359 - 1366.
  • 7Adams JM,Cory S. The Bel-2 apoptotic switch in cancerdevelopment and therapy. Oncogene,2007 ; 26(9) :1324 -1337.
  • 8Dive C. Avoidance of apoptosis as a mechanism of drug resistance.J Intern Med Suppl,1997 ; 740:139-145.
  • 9Azuma T,Yao S,Zhu G,et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood,2008 ; 111(7) :3635-3643.
  • 10Iwai Y,Ishida M,Tanaka Y,et al. Involvement of PD-L1 ontumor cells in the escape from host immune system and tumorimmunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA,2002 ; 99(19) :122 -193.

共引文献11

同被引文献27

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部